Story perspectives

Breakthrough Gene Therapy Shows Promise for Canavan Disease

9/18/2025

39 6

Summary

Story summary

Canavan disease (CD) is a fatal genetic disorder caused by mutations in the ASPA gene, resulting in neurological decline and early death.
A Phase I/II trial of MYR-101, a gene therapy for oligodendrocytes, showed significant improvements in white matter and enzyme activity in eight children.
All reported adverse events during the trial were mild and resolved.
The SYNRGY trial for gene therapy CAP-002 was paused following the death of the first patient, with ongoing investigations.
Fujifilm introduced a new cell culture medium to improve gene therapy production.

1 of 1

Story summary

Canavan disease (CD) is a fatal genetic disorder caused by mutations in the ASPA gene, resulting in neurological decline and early death.
A Phase I/II trial of MYR-101, a gene therapy for oligodendrocytes, showed significant improvements in white matter and enzyme activity in eight children.
All reported adverse events during the trial were mild and resolved.
The SYNRGY trial for gene therapy CAP-002 was paused following the death of the first patient, with ongoing investigations.
Fujifilm introduced a new cell culture medium to improve gene therapy production.